Publication – April 1, 2016
April 1, 2016
Officially at Guelph
September 6, 2016

The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death

Acute myeloid leukemia (AML) is a devastating hematological malignancy characterized by the accumulation of myeloid progenitors that fail to terminally differentiate.[1] Standard induction therapy consists of 7 days of cytarabine followed by 3 days of an anthracycline (typically daunorubicin) treatment. Remission rates for patients younger than 60 years of age are 60–80%, decreasing to 40–50% in older patients [1] while the five-year survival rate for
patients older than 60 is only 10%.[1] Second-line induction or postrelapse regimens rely 

Leave a Reply